<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD</h1>

    <table>
      <tr><th>Ticker</th><td>OCUL</td></tr>
      <tr><th>Float</th><td>190 M</td></tr>
      <tr><th>IO</th><td>83.58%</td></tr>
      <tr><th>MC</th><td>2.4 </td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Ocular Therapeutix (NASDAQ: OCUL) reported positive topline SOL-1 Phase 3 results for AXPAXLI (OTX-TKI) in wet AMD. In a 344-subject, FDA-aligned SPA superiority trial comparing a single 0.45 mg AXPAXLI dose to a single 2 mg aflibercept dose, the Week 36 primary endpoint was met: 74.1% of AXPAXLI subjects maintained vision (<15 ETDRS letter loss) vs. 55.8% for aflibercept (risk difference 17.5%, p=0.0006). The Week 52 durability assessment was also met (65.9% vs. 44.2%; risk difference 21.1%, p<0.0001). Rescue-free rates favored AXPAXLI at Weeks 24/36/52 (80.6%, 74.7%, 68.8% vs. 72.1%, 56.4%, 47.7%). CSFT control at Week 36 favored AXPAXLI (55.9% vs. 37.8%; nominal p=0.0013). AXPAXLI was generally well tolerated with no treatment-related ocular or systemic serious adverse events reported through the Week 52 database lock. Ocular intends to pursue an NDA based on SOL-1 pending formal FDA discussions; complementary SOL-R non-inferiority trial topline data expected 1Q 2027.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Met primary superiority endpoint at Week 36 under FDA-aligned SPA (74.1% vs. 55.8%; risk difference 17.5%, p=0.0006).</li><li>Met Week 52 durability assessment (65.9% vs. 44.2%; risk difference 21.1%, p<0.0001).</li><li>Higher protocol rescue-free rates at Weeks 24/36/52 versus aflibercept (80.6%, 74.7%, 68.8% vs. 72.1%, 56.4%, 47.7%).</li><li>Superior CSFT control at Week 36 (55.9% vs. 37.8%; nominal p=0.0013).</li><li>No treatment-related ocular or systemic serious adverse events observed through Week 52 data lock.</li><li>Trial conducted under an FDA SPA; company plans to seek NDA based on SOL-1 data.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>NDA submission and regulatory acceptance remain subject to formal discussions with the FDA (no approval guaranteed).</li><li>Week 52 CSFT difference had nominal p=0.1094 (not statistically significant).</li><li>SOL-R non-inferiority trial results not yet available (topline expected 1Q 2027).</li><li>SOL-1 used a selected population with a loading segment prior to randomization, which may affect generalizability.</li><li>Follow-up continues through Week 104; longer-term safety/efficacy data are still pending.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/b7347dfe-a20e-4bce-8c4b-e072c185762a" target="_blank">Original Article</a>
    </div>

    <div class="small">OCUL • TradersLink AI News</div>
  </div>
</body>
</html>